The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has opened a consultation on new regulations for applications for subsidy and pricing of medicines. The draft would replace the current framework and move a set of company-facing requirements out of guidance and into binding text.
The proposal follows TLV's consultation of 22 December 2025 on new general guidelines for subsidy and pricing. In that earlier round, the agency suggested placing the application requirements in an annex to the guidelines and in the company handbook used for applications. After some consultees objected to requirements aimed at individual applicants being set out in non-binding material, TLV now proposes to include them in regulations instead.
The draft makes several substantive changes to the application rules. It would give the regulations a new name, adjust the definition of a new medicine, add a definition of parallel distribution, and introduce a new rule on the information that all applications must contain. TLV also proposes to revise the rule for applications for new medicines and to add a separate rule for applications under the simplified procedure for medicines containing an established substance.
The agency has not altered the underlying subsidy model. It has, however, chosen to set out more of the expected submission content in formal rules rather than supporting documents. That gives applicants a clearer reference point at the start of the process and narrows the space for dispute over which materials TLV can require.
TLV proposes that the new regulations enter into force on 1 July 2026, with comments due by 10 April 2026. That leaves the agency a short window to refine the draft before it finalises the text.
The change is procedural rather than structural, but it should make Swedish reimbursement applications more explicit and more uniform, particularly for companies preparing first submissions or using the simplified route for established substances.
Source: Tandvårds- och läkemedelsförmånsverket, TLV
Link: Remiss om nya föreskrifter för ansökan om subvention och prissättning av läkemedel (Consultation on new regulations for applications for subsidy and pricing of medicines)
Date: 20 March 2026
